Document 0654
 DOCN  M9480654
 TI    [The stakes in preventing opportunistic MAI infections in AIDS. From an
       interview with Dr. Patrick Philibert]
 DT    9410
 AU    Philibert P
 SO    Allerg Immunol (Paris). 1994 Apr;26(4):145-8. Unique Identifier :
       AIDSLINE MED/94304497
 AB    Development of HIV infection is littered with many pathological episodes
       of which the physical and psychological repercussions on the patient are
       full of consequences. In this context, full co-operation between the
       hospital services and general practitioners is fundamental, from the
       moment of the announcement of seropositivity, to place under
       anti-retroviral treatment and to follow the pathological events.
       Opportunistic infections that threaten the life of the patient are
       severe because of the fall in the level of CD4 lymphocytes. Nowadays it
       is important to start prophylactic treatments and to make the patient
       understand the fight to follow these treatments that alone can help to
       maintain his autonomy and quality of life. The quality of the
       relationship established between the practitioner and patient is here
       very important. At the start of prophylactic treatment for several
       opportunistic infections in AIDS, such as pneumocystosis or
       toxoplasmosis, it is essential to have available an effective
       therapeutic strategy for infection by Mycobacterium avium complex (MAC).
       In effect, these serious infections following after the development of
       AIDS, graviously threaten the life of patients and their probability to
       survive. Today, practitioners have available rifabutine (Ansatipine)
       which is an efficacious treatment for MAC infections. It is sure that
       many patients will find benefit.
 DE    Antiviral Agents/THERAPEUTIC USE  AIDS-Related Opportunistic
       Infections/EPIDEMIOLOGY/MICROBIOLOGY/  *PREVENTION &
       CONTROL/PARASITOLOGY  English Abstract  Human  HIV Infections/DRUG
       THERAPY  Leukocyte Count  Mycobacterium avium-intracellulare
       Infection/EPIDEMIOLOGY/  *PREVENTION & CONTROL  Rifabutin/THERAPEUTIC
       USE  T4 Lymphocytes  INTERVIEW  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).